Literature DB >> 11303830

Airflow limitation during respiratory syncytial virus lower respiratory tract infection predicts recurrent wheezing.

L Bont1, W M Van Aalderen, J Versteegh, F Brus, J T Draaisma, M Pekelharing-Berghuis, R A Van Diemen-Steenvoorde, J L Kimpen.   

Abstract

BACKGROUND: Respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI) is frequently followed by recurrent wheezing. Thus far no clinical risk factors have been identified to predict which infants will have wheezing episodes subsequent to RSV LRTI.
OBJECTIVE: To determine clinical predictors for airway morbidity after RSV LRTI.
METHODS: In a 1-year follow-up study we investigated the predictive value of auscultatory findings characteristic of airflow limitation (wheezing) during RSV LRTI for subsequent airway morbidity. Clinical characteristics, including the presence or absence of signs of airflow limitation, of hospitalized infants with RSV LRTI were prospectively recorded during 2 winter epidemics. During a 1-year follow-up period parents of 130 infants recorded daily airway symptoms. OUTCOME MEASURE: Recurrent wheezing defined as > or = 2 episodes of wheezing.
RESULTS: Signs of airflow limitation during RSV LRTI were absent in 47 (36%) infants and present in 83 (64%) infants. Recurrent wheezing was recorded in 10 (21%) infants without signs of airflow limitation and in 51 (61%) with signs of airflow limitation during initial RSV LRTI (relative risk, 0.29, P < 0.001). In a multiple logistic regression model, airflow limitation during initial RSV LRTI proved independent from other clinical parameters, including age, parental history of asthma and smoke exposure.
CONCLUSIONS: A sign of airflow limitation during RSV LRTI is the first useful clinical predictor for subsequent recurrent wheezing.

Entities:  

Mesh:

Year:  2001        PMID: 11303830     DOI: 10.1097/00006454-200103000-00012

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  6 in total

Review 1.  Mechanisms how mucosal innate immunity affects progression of allergic airway disease.

Authors:  Allan R Brasier
Journal:  Expert Rev Respir Med       Date:  2019-02-13       Impact factor: 3.772

Review 2.  The Burden and Long-term Respiratory Morbidity Associated with Respiratory Syncytial Virus Infection in Early Childhood.

Authors:  Brigitte Fauroux; Eric A F Simões; Paul A Checchia; Bosco Paes; Josep Figueras-Aloy; Paolo Manzoni; Louis Bont; Xavier Carbonell-Estrany
Journal:  Infect Dis Ther       Date:  2017-03-29

Review 3.  Targeting inducible epigenetic reprogramming pathways in chronic airway remodeling.

Authors:  Allan R Brasier; Istvan Boldogh
Journal:  Drugs Context       Date:  2019-10-23

4.  The effect of high dose inhaled corticosteroids on wheeze in infants after respiratory syncytial virus infection: randomised double blind placebo controlled trial.

Authors:  Marieke J J Ermers; Maroeska M Rovers; Job B van Woensel; Jan L L Kimpen; Louis J Bont
Journal:  BMJ       Date:  2009-03-31

Review 5.  Prevention and treatment of respiratory syncytial virus bronchiolitis and postbronchiolitic wheezing.

Authors:  Jan L L Kimpen
Journal:  Respir Res       Date:  2002

Review 6.  A systematic review of predictive models for asthma development in children.

Authors:  Gang Luo; Flory L Nkoy; Bryan L Stone; Darell Schmick; Michael D Johnson
Journal:  BMC Med Inform Decis Mak       Date:  2015-11-28       Impact factor: 2.796

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.